Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative
drug-delivery platform DehydraTECH(TM) alters the way cannabinoids enter the
bloodstream, which results in increased absorption. A recent article discussing
LXRP reads, “Its proprietary technology promises multiple advantages in
cannabinoid edibles. First, it masks the undesirable taste typically found in cannabinoid
edibles, eliminating the need to add sweetening agents and enabling sugar-free
options. Second, it increases the product’s absorption rate, with absorption
occurring at two- to five-times higher rates than other edibles. Finally, it
reduces the time of onset; effects of the product are felt within 15–20 minutes
of consumption rather than the typical 60–120 minutes. In a March 2016 focus
study, subjects ranked Lexaria’s formulation as the best tasting and most
palatable option. They also found it to deliver the highest-quality THC
experience overall.”
To view the full article, visit http://ibn.fm/ZkEsd
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
